Bardoxolone (Standard)
Bardoxolone (Standard) (CDDO (Standard); RTA 401 (Standard)) is the analytical standard of Bardoxolone (CDDO; RTA 401) (HY-14909). This product is intended for research and analytical applications. Bardoxolone (CDDO; RTA 401) is an Nrf2 pathway activator and SARS-CoV-2 3CLpro inhibitor. Bardoxolone exerts antiviral, anti-inflammatory, and apoptosis (Apoptosis)-inducing effects by reversibly covalently binding to SARS-CoV-2 3CLpro (Kd = 25.90 μM) and Keap1, forming a Michael adduct with IKK to inhibit NF-κB, binding to PPAR-γ to induce differentiation, and selectively inhibiting Lonp1 without inhibiting the proteasome. Bardoxolone can be used for research on COVID-19 and cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98%
- No. CAS: 218600-44-3
- Fòrmula: C31H41NO4
- Peso molecular:491.66
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-14909
BardoxoloneNrf2 Pathway Activator/SARS-CoV-2 3CLpro Inhibitor -
HY-17363
Dimethyl fumarateNrf2 Activator -
HY-13755
SulforaphaneKeap1/Nrf2/ARE Inducer -
HY-12212
OmaveloxoloneNrf2 Activator -
HY-112675
4-Octyl itaconateNrf2 Activator -
HY-13324
Bardoxolone methylNrf2 Activator -
HY-19734
NK-252Nrf2 Activator -
HY-N0290
MangiferinNrf2 Activator -
HY-100523
ML385Nrf2 Inhibitor -
HY-18738
Pyrrolidinedithiocarbamate ammoniumSelective NF-κB Inhibitor -
HY-13982
JSH-23NF-κB Inhibitor -
HY-17363R
Dimethyl fumarate (Standard)Nrf2 Activator
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 218600-44-3
-
Peso molecular 491.66
-
Fòrmula C31H41NO4
-
SMILES
CC1(C)CC[C@@]2(C(O)=O)[C@@]([C@](C(C=C3[C@@]4(C)CC[C@]5([H])[C@]3(C)C=C(C#N)C(C5(C)C)=O)=O)([H])[C@@]4(C)CC2)([H])C1
-
Synonyms
CDDO (Standard); RTA 401 (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Sun Q, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
[2]. Borella R, et al. Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids. Molecules. 2019;24(22):4097. Published 2019 Nov 13. [Content Brief]
[3]. Wang Y, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2021;212:113030. [Content Brief]
[4]. Borella R, et al. Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids. Molecules. 2019 Nov 13;24(22):4097. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bardoxolone (Standard) Related Classifications
HY-14909R Related Classifications
Powered by Bioz
Keywords
- Bardoxolone (Standard)
- 218600-44-3
- CDDO (Standard)
- RTA 401 (Standard)
- Reference Standards
- Keap1-Nrf2
- SARS-CoV
- IKK
- NF-κB
- PPAR
- Apoptosis
- SARS coronavirus
- IκB kinase
- I kappa B kinase
- Nuclear factor-κB
- Nuclear factor-kappaB
- Peroxisome proliferator-activated receptors
- COVID-19
- Keap1
- Lonp1
- Nrf2
- PPAR-γ
- SARS-CoV-2
- SARS-CoV-2 3CLpro
- USP7
- necroptosis
- Inhibitor
- inhibitor
- inhibit